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Signs	&	Symptoms
Underlying	PathophysiologyGuillain-Barre	Syndrome	consists	of	a	group	 of	neuropathic	 conditions	characterized	by	progressive	weakness	and	diminished	or	absent	myotatic	reflexes.	The	estimated	annual	incidence	in	the	United	States	is	1.65	 to	1.79	 per	100,000	 persons	 (Walling	&	Dickson,	2013).	 Understanding	 how	this	condition	progresses	and	 the	affects	it	has	on	a	patient	will	assistant	in	providing	optimal	patient	care	as	a	future	nurse	anesthetist.	As	stated	by	 	Turakhia,	P.,	Barrick,	B.,	 and	Berman,	 J.	 (2013)	 “the	anesthetic	implications	for	the	various	comorbidities	are	varied	and	can	be	profound”	 (p.	1).	An	individual	who	suffers	from	Guillain-Barre	is	a	patient	who	certainly	requires	critical	care	management	 in	order	 to	avoid	complications	associated	with	the	disease.	Being	aware	of	the	pathophysiology,	 risk	factors,	signs	and	symptoms,	and	treatment	 involved	in	caring	for	Guillain-Barre	Syndrome	can	better	prepare	 the	advanced	practicing	nurse	 for	patients	suffering	 from	this	condition.
Significance	of	PathophysiologyIt	is	of	utmost	 importance	 to	understand	 the	pathophysiology	of	Guillain-Barre	Syndrome.	 Having	an	understanding	 of	how	 it	progresses	and	manifests	itself	can	lead	to	quick	diagnosis	and	 intervention.	Prevention	of	 life-threatening	complications	remains	the	cornerstone	of	 supportive	care.	Progressive	demyelination	of	the	phrenic	nerve,	 innervating	 the	diaphragm,	may	 lead	to	acute	respiratory	 muscle	paralysis.	Early	detection	of	 respiratory	 failure	and	anticipation	of	mechanical	ventilation	are	crucial	to	avoid	emergency	 intubation	and	cardiopulmonary	 arrest.	Life-threatening	episodes	of	hemodynamic	 instability	related	to	autonomic	dysfunction	may	occur	 in	GBS	patients.	They	should	be	admitted	 to	the	hospital	for	 close	monitoring	of	respiratory	 status,	hemodynamic	 instability,	and	autonomic	dysfunction	 (Sebastian,	2012).
Guillain	Barre	Syndrome	 can	occur	in	any	patient.	 It	 typically	involves	initial	insult	from	injury	or	is	preceded	by	an	infection,	leading	to	demyelination	of	the	nerves.	Understanding	 risk	factors	and	how	GBS	presents	itself	can	aid	in	early	diagnosis.	It	is	detrimental	that	those	caring	 for	patients	be	educated	on	 the	signs	and	symptoms,	and	be	prepared	 to	intervene	as	necessary	to	reduce	 the	riskofcomplications.	Interdisciplinary	collaboration	and	careful	management	can	help	reduce	 the	 length	of	 recovery	and	promote	better	outcomes	for	affected	individuals.	According	to	Dubey	et	al.	(2016)	 “early	identification	of	GBS	may	lead	to	earlier	 initiation	of	management,	 including	 immunomodulatory	 therapy,	 intensive	care	unit	admission	in	selected	patients,	and	multidisciplinary	team	involvement.	The	initial	clinical	diagnosis	of	GBS	may	be	challenging.	Lack	of	evaluation	by	a	neurologist,	neuropathic	 pain,	preserved	reflexes,	and	an	atypical	pattern	of	weakness	were	all	associated	with	a	delay	in	considering	 the	diagnosis	of	GBS.	The	delay	in	diagnosis	had	a	 significant	impact	on	outcome,	as	assessed	by	the	clinical	status	at	the	time	of	discharge	and	the	discharge	disposition”	(p.	386).	 It	 is	of	the	utmost	 importance	 that	nurses	 identify	signs	of	a	potential	case	of	GBS	as	soon	as	possible	in	order	 to	promote	 an	optimal	outcome	 for	patients.	The	primary	 nursing	management	of	a	patient	with	GBS	should	be	centered	on	problems	with	the	airway	related	 to	respiratory	muscle	weakness	or	paralysis,	decreased	cough	reflex,	and	 immobilization.	Due	to	 the	progressive	muscle	weakness,	nurses	should	plan	interventions	 that	focus	on	preventing	 complications	related	to	immobility,	such	as	ensuring	skin	integrity.	 (Moore	&	Shepard,	 2014).
The	first	symptoms	include	varying	degrees	of	weakness	or	tingling	sensations	in	the	legs,	that	 can	spread	 to	the	upper	body.	 This	can	progress	to	almost	complete	paralysis.	Common	symptoms	are:	Facial	droop,	 diplopias,	dysarthria,	dysphagia,	ophthalmoplegia,	pupillary	disturbances,	dyspnea	on	exertion,	 shortness	of	breath,	difficulty	swallowing,	slurred	speech.	Autonomic	Symptoms	 include:	Tachycardia,	bradycardia,	 facial	flushing,	paroxysmal	hypertension,	 orthostatic	hypotension,	diaphoresis,	urinary	retention.	 Required	criteria	for	 the	diagnosis	include:	Progressive	weakness	of	more	than	 two	limbs,	areflexia,	progression	 for	no	more	than	 four	weeks	(Sebastian,	2012).	Supportive	 criteria	include:	Relatively	mild	sensory	signs,	raised	protein	 in	the	cerebrospinal	 fluid	(CSF),	 with	a	relatively	normal	cell	count,	neurophysiological	evidence	of	conduction	block,	weakness	is	frequently	proximal	and	distal,	unlike	dying	back	axonopathies,	and	respiratory	involvement	occurs	 in	about	a	quarter	 of	cases.	The	CSF	protein	 may	be	normal	 in	the	 first	week	of	the	illness,	but	may	 then	rise	to	several	g/dl.	The	CSF	cell	count	usually	remains	below	500	 cells/litre.	Oligoclonal	bands	are	sometimes	found	 in	the	CSF.	Routine	blood	 tests	sometimes	reveal	a	raised	sedimentation	rate	with	hyponatraemia	 from	 inappropriate	antidiuretic	hormone	 release,	and	mild	impairment	of	liver	function	 tests	is	not	uncommon	(Winer,	2001).
Subtypes	of	GBS	include	AIDP,	AMAN,	acute	motor	and	sensory	axonal	neuropathy	(AMSAN),	acute	sensory	axonal	neuropathy	 (ASAN),	and	Miller–Fisher	syndrome.	Electrophysiology	is	an	 important	clinical	tool	for	distinguishing	demyelinating	and	axonal	subtypes,	because	it	may	reveal	demyelination,	 loss	of	motor	axons	only,	loss	of	sensory	axons	only,	or	mixed	loss	(Franssen	&	Straver,	2014).	 Proposed	 mechanism	involves	an	antecedent	 infection	leading	to	an	autoimmune	response	reacting	with	peripheral	nerve	components.	Most	of	 the	pathogens	gains	entry	 to	 the	body	 through	mucosal	or	gut	epithelium	and	 induce	antibody	production	 against	specific	gangliosides	in	myelin.	Proposed	mechanism	involves	an	antecedent	 infection	leading	to	an	autoimmune	response	reacting	with	peripheral	nerve	components.	Most	of	 the	pathogens	gains	entry	 to	the	body	 through	 mucosal	or	gut	epithelium	and	 induce	antibody	production	 against	specific	gangliosides	in	myelin.	The	immune	response	depends	on	bacterial	factors,	such	as	the	specificity	of	lipo-oligosaccharide	(LOS),	and	on	host	factors,	 such	as	genetic	polymorphism	and	 immune	status.	The	presence	of	antibodies	leads	to	activation	of	T	cells	and	complements,	leading	to	a	cascade	of	inflammation	and	demyelination.	The	demyelination	decreases	the	velocity	of	nerve	conduction	and	slows	the	impulse	transmission	along	the	axons.	The	extent	of	nerve	damage	varies,	with	more	damage	seen	in	the	 intensely	myelinated	peripheral	nerves,	causing	motor	and	sensory	weakness	(Sebastian,	2012).Based	on	human	observational	studies	and	data	obtained	 from	EAN	models,	it	is	hypothesized	that	CCR2	monocytes	cross	the	brain	nerve	barrier	 (BNB)	via	interaction	with	Schwann-cell-secreted	CCL2	expressed	by	 the	BNB	endothelium.	These	monocytes	differentiate	into	endoneurial	macrophages	 that	migrate	to	CCL2-expressing	Schwann	cells	to	induce	demyelination.	CCR1/CCR5	 macrophages	may	migrate	to	axons	expressing	CCL5	 to	induce	axonal	degeneration.	 CXCR3	T	cells	may	migrate	across	the	BNB	via	interactions	with	BNB	endothelium	CXCL10	 and	directly	contribute	 to	nerve	 injury	via	cytokine	secretion	or	expression	of	pro-inflammatory	chemokines	that	further	 attract	hematogenous	monocytes	and	 lymphocytes,	enhancing	 the	 inflammatory	process	(Chiang	&	Ubogu,	2013).
Treatment
Based	on	strong	research	evidence	in	adults,	IVIG	and	plasma	exchange	hasten	recovery	from	GBS	in	patients	with	impaired	ability	to	ambulate	(Rosen,	2012).	 Common	treatment	modalities	include	corticosteroids,	intravenous	immunoglobulin	 (IVIg),	therapeutic	plasma	exchange	(TPE),	 cerebral	 spinal	fluid	(CSF)	 filtration,	and	immunoadsorption.	 Treatment	with	intravenous	 immunoglobulin	and	plasma	exchange	reduces	 the	time	for	 recovery	 to	occur,	although	some	remain	disabled	(McNair,	2013).
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